JP2015523362A5 - - Google Patents

Download PDF

Info

Publication number
JP2015523362A5
JP2015523362A5 JP2015520531A JP2015520531A JP2015523362A5 JP 2015523362 A5 JP2015523362 A5 JP 2015523362A5 JP 2015520531 A JP2015520531 A JP 2015520531A JP 2015520531 A JP2015520531 A JP 2015520531A JP 2015523362 A5 JP2015523362 A5 JP 2015523362A5
Authority
JP
Japan
Prior art keywords
cells
urolithin
pharmaceutical composition
disease
food
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015520531A
Other languages
English (en)
Japanese (ja)
Other versions
JP6422163B2 (ja
JP2015523362A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/048310 external-priority patent/WO2014004902A2/en
Publication of JP2015523362A publication Critical patent/JP2015523362A/ja
Publication of JP2015523362A5 publication Critical patent/JP2015523362A5/ja
Application granted granted Critical
Publication of JP6422163B2 publication Critical patent/JP6422163B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015520531A 2012-06-27 2013-06-27 ウロリチンまたはその前駆体の投与によるオートファジーの増強または寿命の延長 Active JP6422163B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261665137P 2012-06-27 2012-06-27
US61/665,137 2012-06-27
US201261712886P 2012-10-12 2012-10-12
US61/712,886 2012-10-12
US201361791137P 2013-03-15 2013-03-15
US61/791,137 2013-03-15
PCT/US2013/048310 WO2014004902A2 (en) 2012-06-27 2013-06-27 Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018140453A Division JP6879980B2 (ja) 2012-06-27 2018-07-26 ウロリチンまたはその前駆体の投与によるオートファジーの増強または寿命の延長

Publications (3)

Publication Number Publication Date
JP2015523362A JP2015523362A (ja) 2015-08-13
JP2015523362A5 true JP2015523362A5 (https=) 2016-10-06
JP6422163B2 JP6422163B2 (ja) 2018-11-14

Family

ID=48782652

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2015520531A Active JP6422163B2 (ja) 2012-06-27 2013-06-27 ウロリチンまたはその前駆体の投与によるオートファジーの増強または寿命の延長
JP2018140453A Active JP6879980B2 (ja) 2012-06-27 2018-07-26 ウロリチンまたはその前駆体の投与によるオートファジーの増強または寿命の延長
JP2021077856A Active JP7339296B2 (ja) 2012-06-27 2021-04-30 ウロリチンまたはその前駆体の投与によるオートファジーの増強または寿命の延長
JP2023097670A Pending JP2023107934A (ja) 2012-06-27 2023-06-14 ウロリチンまたはその前駆体の投与によるオートファジーの増強または寿命の延長
JP2025135511A Pending JP2025161884A (ja) 2012-06-27 2025-08-15 ウロリチンまたはその前駆体の投与によるオートファジーの増強または寿命の延長

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018140453A Active JP6879980B2 (ja) 2012-06-27 2018-07-26 ウロリチンまたはその前駆体の投与によるオートファジーの増強または寿命の延長
JP2021077856A Active JP7339296B2 (ja) 2012-06-27 2021-04-30 ウロリチンまたはその前駆体の投与によるオートファジーの増強または寿命の延長
JP2023097670A Pending JP2023107934A (ja) 2012-06-27 2023-06-14 ウロリチンまたはその前駆体の投与によるオートファジーの増強または寿命の延長
JP2025135511A Pending JP2025161884A (ja) 2012-06-27 2025-08-15 ウロリチンまたはその前駆体の投与によるオートファジーの増強または寿命の延長

Country Status (16)

Country Link
US (10) US11020373B2 (https=)
EP (3) EP4233858B1 (https=)
JP (5) JP6422163B2 (https=)
KR (4) KR102317160B1 (https=)
CN (2) CN105142632B (https=)
AR (1) AR091604A1 (https=)
AU (6) AU2013284419A1 (https=)
BR (1) BR112014032809A8 (https=)
CA (3) CA3291904A1 (https=)
DK (1) DK4233858T3 (https=)
ES (2) ES3032009T3 (https=)
MX (3) MX393128B (https=)
PL (1) PL4233858T3 (https=)
PT (2) PT2866804T (https=)
SG (3) SG10202106329TA (https=)
WO (1) WO2014004902A2 (https=)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3291904A1 (en) 2012-06-27 2026-03-02 Amazentis Sa Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof
US20160045472A1 (en) * 2013-01-18 2016-02-18 Procell Sprl Urolithin b for muscle growth
WO2015035358A1 (en) 2013-09-09 2015-03-12 Natreon, Inc. Regulation of steroidogenic activity by using purified shilajit
EP2862568A1 (en) 2013-10-15 2015-04-22 Centre National de la Recherche Scientifique (CNRS) Compositions comprising urolithins and uses thereof for the stimulation of insulin secretion
US9394269B2 (en) 2013-12-23 2016-07-19 Amazentis Sa Process-scale synthesis of urolithins
GB201323008D0 (en) 2013-12-24 2014-02-12 Amazentis As Compounds and uses thereof
GB201413228D0 (en) * 2014-07-25 2014-09-10 Nugerontix Ltd Polyphenol compositions
WO2016099947A1 (en) * 2014-12-19 2016-06-23 Halo Life Science, Llc Use of ellagic acid dihydrate in food products and nutraceuticals
WO2016167225A1 (ja) * 2015-04-13 2016-10-20 住友精化株式会社 ２－ハロゲン化安息香酸類の製造方法
JP6740548B2 (ja) * 2015-05-15 2020-08-19 公立大学法人岡山県立大学 ウロリチン類を含有する育毛剤、及び、ウロリチン類を含有する５αレダクターゼ活性阻害剤
JP2017014154A (ja) * 2015-07-01 2017-01-19 公立大学法人岡山県立大学 ウロリチン類を含有するヒアルロン酸産生促進剤
JP6799767B2 (ja) * 2015-07-07 2020-12-16 公立大学法人岡山県立大学 ウロリチン類を含有するメラニン産生抑制剤
GB201515391D0 (en) 2015-08-28 2015-10-14 Amazentis Sa Compositions
EP3393467B1 (en) * 2015-12-24 2020-07-01 Amazentis SA Compositions comprising nicotinamide riboside and a urolithin
JP6791478B2 (ja) * 2016-05-26 2020-11-25 株式会社ダイセル ウロリチン類を含有するアンジオテンシン変換酵素阻害剤
JP2017210444A (ja) * 2016-05-26 2017-11-30 株式会社ダイセル ウロリチン類を含有するリパーゼ阻害剤
ES2985944T3 (es) * 2016-06-29 2024-11-07 Halo Life Science Llc Método de preparación de una sal de ellagato de dicolinio de poco olor y otras sales orgánicas de colina de poco olor
US10774328B2 (en) 2016-07-11 2020-09-15 University Of North Texas Health Science Center At Fort Worth Treatment for glaucoma and other eye diseases
WO2018085419A1 (en) 2016-11-01 2018-05-11 Jian Feng Method of producing naive pluripotent stem cells
EP3354645A1 (en) 2017-01-26 2018-08-01 Patheon Austria GmbH & Co KG Process for preparing urolithins
EP3592425A1 (en) * 2017-03-08 2020-01-15 Amazentis SA Methods for improving mitophagy in subjects
US20180256471A1 (en) 2017-03-08 2018-09-13 Amazentis Sa Skin Treatment Methods
EP4553071A3 (en) 2017-03-08 2025-07-23 Amazentis SA Methods for improving mitophagy in subjects
JP2019097566A (ja) * 2017-12-07 2019-06-24 大正製薬株式会社 体内時計調整用組成物
US20200384064A1 (en) * 2017-12-20 2020-12-10 Societe Des Produits Nestle S.A. Compositions and methods using high protein for induction of autophagy
CA3086250A1 (en) * 2017-12-20 2019-06-27 Societe Des Produits Nestle S.A. Compositions and methods using a combination of autophagy inducer and high protein for induction of autophagy
CN111727040A (zh) * 2018-02-19 2020-09-29 纳特雷恩公司 用于改善认知能力或认知功能的尿石素a和b的协同组合
WO2019163176A1 (ja) 2018-02-21 2019-08-29 株式会社ダイセル ウロリチン類を含有する破骨細胞分化抑制剤
IL276886B2 (en) * 2018-02-27 2024-11-01 Amazentis Sa Urolitin A synthesis process
WO2019187918A1 (ja) * 2018-03-29 2019-10-03 国立大学法人 琉球大学 分化コントロール化合物を用いて造腫瘍性をもつおそれのある未分化ｉＰＳ細胞等の混入を除去する方法
JP7557374B2 (ja) * 2018-04-30 2024-09-27 アマゼンティス エスアー 免疫増強剤としてのウロリチンａ
KR20210042264A (ko) 2018-05-15 2021-04-19 유니버시티 오브 루이빌 리서치 파운데이션, 인코포레이티드 요법에서의 사용을 위한 우롤리틴 a 및 그의 유도체
WO2019236765A1 (en) * 2018-06-05 2019-12-12 Flagship Pioneering Innovations V, Inc. Acylated catechin polyphenols and methods of their use for the treatment of cancer
CA3102404A1 (en) 2018-06-05 2019-12-12 Flagship Pioneering Innovations V, Inc. Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
CN108676013B (zh) * 2018-06-25 2021-01-01 中国医学科学院医药生物技术研究所 具有自噬激活活性的黄醇酮类化合物、其制备方法及其制药应用
CN109316478A (zh) * 2018-11-06 2019-02-12 上海出入境检验检疫局动植物与食品检验检疫技术中心 一种尿石素a在制备抗衰老的药物、化妆品中的应用及药物、化妆品
PL245399B1 (pl) 2018-11-29 2024-07-15 Univ Warszawski Medyczny Kompozycja farmaceutyczna zawierająca urolitynę A lub jej pochodną do zastosowania zewnętrznego miejscowego w leczeniu, hamowaniu i zapobieganiu chorobom skóry i błon śluzowych o podłożu zapalnym
JP7677893B2 (ja) * 2019-01-18 2025-05-15 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 幹細胞機能を向上させるための薬剤及び方法
CN110066284B (zh) * 2019-02-01 2021-06-04 贵阳倍隆生物科技有限公司 一种一锅法合成鞣花酸的方法
CN110229167B (zh) * 2019-05-22 2020-11-24 珠海萱嘉君行健康产业发展有限公司 一种利用五倍子制备鞣花酸的方法、制得的鞣花酸及其应用
CN111995610A (zh) * 2019-05-27 2020-11-27 首都医科大学 一种尿石素类化合物用于治疗胶质母细胞瘤药物的应用
US20200397807A1 (en) * 2019-06-18 2020-12-24 MitoPower, LLC Nicotinyl riboside compounds and their uses
US20220184015A1 (en) * 2019-06-20 2022-06-16 Societe Des Produits Nestle S.A. Compositions and methods to potentiate musculoskeletal effect of one or more anabolic amino acids on bone health
GB201912107D0 (en) * 2019-08-22 2019-10-09 Amazentis Sa Combination
GB201915191D0 (en) 2019-10-21 2019-12-04 Floratek Gmbh Novel heterocyclic compounds
GB201916046D0 (en) 2019-11-04 2019-12-18 Amazentis Sa Diagnostic method
EP4065102A1 (en) * 2019-11-27 2022-10-05 Société des Produits Nestlé S.A. Benzocoumarin ampk activator compounds, compositions, methods and uses thereof
JP2023503276A (ja) * 2019-11-27 2023-01-27 ソシエテ・デ・プロデュイ・ネスレ・エス・アー Ａｍｐｋ間接活性化化合物と組み合わせたａｍｐｋ直接活性化化合物、組成物、方法、及びそれらの使用
CN113018305A (zh) * 2019-12-24 2021-06-25 兰州大学 一种化合物在制备治疗阿尔兹海默症药物中的应用
CA3168493A1 (en) * 2020-02-20 2021-08-26 The Royal Institution For The Advancement Of Learning/Mcgill University Use of castalagin or analogs thereof for anti-cancer efficacy and to increase the response to immune checkpoint inhibitors
EP4182342A4 (en) * 2020-07-17 2024-08-14 The Trustees of Columbia University in the City of New York Methods and compositions to increase lifespan and healthspan by mimicking the effects of time-restricted feeding
CN111983058B (zh) * 2020-07-30 2023-06-23 云南中医药大学 中药抗非酒精性脂肪肝活性物质的筛选方法
WO2022051643A1 (en) * 2020-09-04 2022-03-10 Natreon, Inc. Methods of treating and preventing hepatotoxicity
CA3188397A1 (en) 2020-09-25 2022-03-31 Anupama Dattatreya Compositions and methods using xanthan gum to stabilize at least one urolithin in an aqueous matrix
KR102623664B1 (ko) 2020-12-10 2024-01-12 서울대학교산학협력단 유로리틴 a를 이용한 당뇨성 알츠하이머병의 치료 조성물 및 치료 방법
WO2022162471A1 (en) 2021-01-27 2022-08-04 Vandria Sa Urolithin derivatives and methods of use thereof
CN112716938A (zh) * 2021-02-25 2021-04-30 新疆医科大学 鞣花酸在制备缓解眼组织病变的药物中的用途
KR102677423B1 (ko) * 2021-09-17 2024-06-21 조선대학교산학협력단 망기페린을 포함하는 자가포식 활성화용 조성물
KR102690860B1 (ko) * 2021-10-13 2024-08-05 한국해양과학기술원 남극 진균 균주 Pleosporales sp. SF-7343 유래 대사화합물을 포함하는 염증질환 예방 또는 치료용 조성물
EP4422614A1 (en) * 2021-10-28 2024-09-04 Société des Produits Nestlé S.A. Compositions and methods using a combination of nutrients to support cognition and emotional health in a mammal
EP4482947A1 (en) 2022-02-24 2025-01-01 Amazentis SA Uses of urolithins
CA3246412A1 (en) 2022-03-22 2023-09-28 Amazentis Sa COMPOSITIONS
WO2023237926A2 (en) * 2022-06-06 2023-12-14 Amazentis Sa Urolithins for improving cardiac function and health
JP2025527175A (ja) * 2022-07-27 2025-08-20 ヴァンドリア エスアー ウロリチン誘導体の治療的使用
CN115433151A (zh) * 2022-09-02 2022-12-06 苏州大学 一种6，7，8-三羟基香豆素的制备方法
CN115581689B (zh) * 2022-10-17 2024-05-14 常州大学 尿石素b酰胺类衍生物的应用
GB202219317D0 (en) 2022-12-20 2023-02-01 Amazentis Sa Methods for improving mitophagy in subjects
GB202308224D0 (en) 2023-06-01 2023-07-19 Amazentis Sa Formulation
CN116966188B (zh) * 2023-07-14 2026-04-03 天津医科大学总医院 丁香素在制备治疗和/或预防炎症性肠病药物中的应用
GB202312220D0 (en) 2023-08-09 2023-09-20 Amazentis Sa Formulation
WO2025076497A1 (en) * 2023-10-06 2025-04-10 Northeast Ohio Medical University Combination treatment of tau pathology
WO2025078645A1 (en) * 2023-10-13 2025-04-17 L'oreal Cosmetic use of at least urolithin b or c on a sensitive skin
FR3153996A1 (fr) * 2023-10-13 2025-04-18 L'oreal Utilisation cosmétique d'au moins l’urolithine C sur une peau sensible
FR3153997A1 (fr) * 2023-10-13 2025-04-18 L'oreal Utilisation cosmétique d'au moins l’urolithine B sur une peau sensible
FR3153998A1 (fr) * 2023-10-13 2025-04-18 L'oreal Utilisation cosmétique d’iso-urolithine A sur une peau sensible
GB202316295D0 (en) 2023-10-24 2023-12-06 Amazentis Sa Composition
GB202319994D0 (en) 2023-12-22 2024-02-07 Amazentis Sa Compositions for use
CN117771237B (zh) * 2024-02-27 2024-05-03 南昌医学院 一种松香烷型二萜化合物的用途和制备方法
WO2025194036A1 (en) * 2024-03-14 2025-09-18 Washington University Autophagy enhancers
WO2025224366A1 (en) 2024-04-26 2025-10-30 Amazentis Sa Immune health improvers
WO2025252771A1 (en) 2024-06-03 2025-12-11 Amazentis Sa Urolithin combinations
WO2025264604A1 (en) * 2024-06-17 2025-12-26 The Procter & Gamble Company Skin care composition and method of using the same
CN118649186A (zh) * 2024-06-28 2024-09-17 大连医科大学附属第二医院 诃子鞣酸在制备用于治疗膀胱癌的药物中的应用
GB202411739D0 (en) 2024-08-08 2024-09-25 Amazentis Sa Compositions
CN119792272B (zh) * 2025-02-07 2025-10-03 陕西中鸿科瑞再生医学研究院有限公司 一种改善睡眠的组合物及其制备方法与制剂

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6479103A (en) 1987-06-09 1989-03-24 Lion Corp External preparation
JPH02304080A (ja) 1989-05-17 1990-12-17 Toyo Pharma- Kk ６Ｈ―ジベンゾ［ｂ，ｄ］ピラン―６―オン誘導体，その製法及び用途
US6066312A (en) 1996-07-16 2000-05-23 Lion Corporation Topical composition for application to the skin containing an ellagic acid-based compound or salt thereof
CA2338638C (en) 1998-07-30 2009-03-17 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of l-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity
KR20000019718A (ko) 1998-09-15 2000-04-15 박호군 탄닌 또는 탄닌 유래 페놀성 화합물을 포함하는 동맥경화증, 고지혈증 및 간질환의 예방 및 치료용 조성물
US20030078212A1 (en) 1998-10-30 2003-04-24 Jia-He Li Pharmaceutical compositions containing poly(adp-ribose) glycohydrolase inhibitors and methods of using the same
US7611738B2 (en) 2005-05-24 2009-11-03 Pom Wonderful, Llc Processes for extracting phytochemicals from pomegranate solids and compositions and methods of use thereof
US7727563B2 (en) 1999-04-19 2010-06-01 Pom Wonderful, Llc Methods of using pomegranate extracts for treating diabetes related atherosclerotic complications in humans
IT1306141B1 (it) * 1999-05-17 2001-05-30 Giampiero Valletta Composizione per il trattamento del prurito uremico e di forme diprurito non riconducibili a lesioni organiche.
US20010047032A1 (en) 1999-12-30 2001-11-29 Castillo Gerardo M. Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases
US6440436B1 (en) 2001-05-18 2002-08-27 Natreon Inc. Process for preparing purified shilajit composition from native shilajit
US20080039179A1 (en) 2001-06-27 2008-02-14 Seelig Jerald C Gaming display with moveable indicator and methods of use
US6953241B2 (en) 2001-11-30 2005-10-11 Brother Kogyo Kabushiki Kaisha Ink-jet head having passage unit and actuator units attached to the passage unit, and ink-jet printer having the ink-jet head
US20050171079A1 (en) 2004-02-04 2005-08-04 Schrimpf Michael R. Amino-substituted tricyclic derivatives and methods of use
US7365193B2 (en) 2004-02-04 2008-04-29 Abbott Laboratories Amino-substituted tricyclic derivatives and methods of use
ES2543981T3 (es) 2004-03-24 2015-08-26 The Regents Of The University Of California Purificaciones de elagitaninos
US20050282781A1 (en) 2004-06-18 2005-12-22 Shibnath Ghosal Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids
US20060257337A1 (en) * 2005-04-28 2006-11-16 David Sherris Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis
JP2009528381A (ja) 2006-02-28 2009-08-06 パロマ ファーマシューティカルズ，インク． 細胞増殖および血管新生を特徴とする疾患を治療する組成物および方法
US8183282B2 (en) * 2006-04-26 2012-05-22 The Regents Of The University Of California Therapeutic uses of urolithins
US8894993B2 (en) 2006-08-04 2014-11-25 Natreon Inc. Mitochondria-targeted antioxidants
US8017147B2 (en) 2008-04-07 2011-09-13 Mazed Mohammad A Nutritional supplement for the prevention of cardiovascular disease, alzheimer's disease, diabetes, and regulation and reduction of blood sugar and insulin resistance
US8367072B2 (en) 2006-12-08 2013-02-05 Polifenoles Naturales, S.L. Composition for treating obesity and method of using the same
US7972633B2 (en) 2007-02-07 2011-07-05 Applied Cognitive Sciences, LLC Nutritional supplements for healthy memory and mental function
WO2008139123A2 (fr) * 2007-05-11 2008-11-20 Galderma Research & Development Preparations pharmaceutiques ou cosmetiques pour application topique et/ou parenterale, leurs procedes de preparation, et leurs utilisations
CA2686511A1 (fr) * 2007-05-11 2008-11-20 Galderma Research & Development Preparations pharmaceutiques ou cosmetiques pour application topique et/ou parenterale, leurs procedes de preparation, et leurs utilisations
US20090105196A1 (en) * 2007-06-22 2009-04-23 Belinda Tsao Nivaggioli Use of creatine compounds to treat dermatitis
EP2033526A1 (en) 2007-09-07 2009-03-11 Probelte Pharma, S.A. Nutritional products comprising pomegranate extracts containing ellagitannins and their use
TW200929211A (en) 2007-12-17 2009-07-01 Etron Technology Inc Method of reducing current of memory in self-refreshing mode
WO2009086303A2 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US20110021618A1 (en) 2008-03-25 2011-01-27 Paloma Pharmaceuticals, Inc. Methods of treating fibrotic disorders
US7927633B2 (en) 2008-03-28 2011-04-19 Janiece Diane Swilling Adaptogenic tea
WO2009153652A2 (en) 2008-06-19 2009-12-23 Avesthagen Limited An extract and a process thereof (pomplex)
US20100004334A1 (en) 2008-07-01 2010-01-07 Mead Johnson Nutrition Company Nutritional Compositions Containing Punicalagins
CN101301319A (zh) 2008-07-09 2008-11-12 中国科学院新疆理化技术研究所 石榴花多酚的制备方法及其应用
US20100055247A1 (en) 2008-08-29 2010-03-04 Tirrito Salvatore J Nutritional Compositions for Athletes
BRPI1010655A2 (pt) * 2009-04-10 2019-09-03 Qi Haiyan novos agentes antienvelhecimento e métodos para identificá-los
JP5385686B2 (ja) 2009-06-05 2014-01-08 サントリーホールディングス株式会社 血小板凝集抑制剤
EP2456772A4 (en) 2009-07-24 2013-02-27 Amazentis Sa COMPOUNDS, COMPOSITIONS AND METHODS FOR CONSERVING HEALTH HEALTH IN NEURODEEGENERATIVE DISEASES
US9005738B2 (en) 2010-12-08 2015-04-14 Buckeye Technologies Inc. Dispersible nonwoven wipe material
PH12022550598A1 (en) 2010-12-23 2024-03-11 Amazentis Sa Compositions and methods for improving mitochondrial function and treating neurodenegenerative diseases and cognitive disorders
WO2012103487A1 (en) 2011-01-27 2012-08-02 New York University Coumarin compounds as melanogenesis modifiers and uses thereof
US9381187B2 (en) 2011-02-16 2016-07-05 Paloma Pharmaceuticals, Inc. Radiation countermeasure agents
EP2678012A1 (en) 2011-02-22 2014-01-01 Institut National de la Santé et de la Recherche Medicale C-glucosidic ellagitannin compounds for use for altering the supramolecular arrangement of actin and for the treatment of osteoporosis, cancer, bacterial infection and viral infection
CA3291904A1 (en) 2012-06-27 2026-03-02 Amazentis Sa Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof
US9394269B2 (en) 2013-12-23 2016-07-19 Amazentis Sa Process-scale synthesis of urolithins
GB201323008D0 (en) 2013-12-24 2014-02-12 Amazentis As Compounds and uses thereof
CA3173584A1 (en) 2014-10-02 2016-04-07 Natreon, Inc. Promoting muscle building and repair and treating disorders related to collagen and pertinent proteins by using shilajit
US10111842B2 (en) 2014-12-31 2018-10-30 University Of Oslo Eutectic solvents and uses thereof
JP2016216378A (ja) 2015-05-15 2016-12-22 公立大学法人岡山県立大学 ウロリチン類を含有する抗糖化剤
JP2017007951A (ja) 2015-06-17 2017-01-12 公立大学法人岡山県立大学 ウロリチンを含有する光老化抑制剤
JP2017014154A (ja) 2015-07-01 2017-01-19 公立大学法人岡山県立大学 ウロリチン類を含有するヒアルロン酸産生促進剤
JP6799767B2 (ja) 2015-07-07 2020-12-16 公立大学法人岡山県立大学 ウロリチン類を含有するメラニン産生抑制剤
JP2017031108A (ja) 2015-08-04 2017-02-09 公立大学法人岡山県立大学 ウロリチン類を含有する、抗しわ剤、コラーゲン産生促進剤、ｍｍｐ−１産生抑制剤、及びエラスターゼ活性阻害剤
GB201515391D0 (en) 2015-08-28 2015-10-14 Amazentis Sa Compositions
GB201515387D0 (en) 2015-08-28 2015-10-14 Amazentis Sa Compositions
KR102546379B1 (ko) 2015-10-22 2023-06-21 에이지씨 가부시키가이샤 배선 기판의 제조 방법
EP3393467B1 (en) 2015-12-24 2020-07-01 Amazentis SA Compositions comprising nicotinamide riboside and a urolithin
US11066381B2 (en) 2016-02-02 2021-07-20 Daicel Corporation Urolithins-containing aqueous solution, dried solid composition thereof and production method therefor, and urolithins stabilizing method
DE202016102778U1 (de) 2016-05-25 2017-08-28 Bobst Bielefeld Gmbh Klapplager
US20180256471A1 (en) 2017-03-08 2018-09-13 Amazentis Sa Skin Treatment Methods
EP4553071A3 (en) 2017-03-08 2025-07-23 Amazentis SA Methods for improving mitophagy in subjects
EP3592425A1 (en) 2017-03-08 2020-01-15 Amazentis SA Methods for improving mitophagy in subjects
US20180296464A1 (en) 2017-04-17 2018-10-18 W Skincare, LLC Autophagy activation nutrient complex, compositions and methods
US10485363B2 (en) 2017-05-21 2019-11-26 Go Smart, Inc. Inflatable pillow with adjustable height
DE102017131226A1 (de) 2017-12-22 2019-06-27 Dewertokin Gmbh Elektromotorischer Möbelantrieb, Möbel und Verfahren zum Erfassen einer Position eines elektromotorischen Möbelantriebs
IL276886B2 (en) 2018-02-27 2024-11-01 Amazentis Sa Urolitin A synthesis process
JP7557374B2 (ja) 2018-04-30 2024-09-27 アマゼンティス エスアー 免疫増強剤としてのウロリチンａ
CN112204248B (zh) 2018-05-28 2026-04-03 Lm风力发电国际技术有限公司 用于风力涡轮机叶片的雷电保护系统的连接元件
US12288430B2 (en) 2018-07-09 2025-04-29 Shimano Inc. Information processing device
US20200085895A1 (en) 2018-09-13 2020-03-19 Verdure Sciences Punicalagin compositions and methods for the treatment of disorders arising from methylglyoxal-induced dna damage
CN109316478A (zh) 2018-11-06 2019-02-12 上海出入境检验检疫局动植物与食品检验检疫技术中心 一种尿石素a在制备抗衰老的药物、化妆品中的应用及药物、化妆品
CN116612991A (zh) 2019-01-28 2023-08-18 京瓷Avx元器件公司 具有超宽带性能的多层陶瓷电容器
CN110244079B (zh) 2019-07-18 2019-12-20 西南石油大学 一种控缝高上浮剂上浮速率的测试方法
GB201910450D0 (en) 2019-07-22 2019-09-04 Iiaa Ltd Cosmetic compositions
US11016804B2 (en) 2019-08-02 2021-05-25 Argo AI, LLC Ahead of time scheduling process for autonomous vehicles
GB201912107D0 (en) 2019-08-22 2019-10-09 Amazentis Sa Combination
CN110368476A (zh) 2019-08-29 2019-10-25 中南大学湘雅医院 一种治疗骨肉瘤的手术辅助药物
GB201916046D0 (en) 2019-11-04 2019-12-18 Amazentis Sa Diagnostic method
DE102020200633A1 (de) 2020-01-21 2021-07-22 Jungheinrich Aktiengesellschaft Doppelpedalsystem für ein Flurförderzeug
US11205053B2 (en) 2020-03-26 2021-12-21 International Business Machines Corporation Semantic evaluation of tentative triggers based on contextual triggers
CA3179442A1 (en) 2020-05-22 2021-11-25 Brian Warrington Compositions for treating acne and dermatological conditions
WO2021237214A1 (en) 2020-05-22 2021-11-25 Ilera Derm LLC Compositions for treating acne and dermatological conditions
WO2022158533A1 (en) 2021-01-20 2022-07-28 Ajinomoto Co., Inc. Cosmetic composition
CN112843049A (zh) 2021-02-02 2021-05-28 邯郸制药股份有限公司 一种组合物用于制备基于调控CDKs和SMAD6基因抑制胃癌细胞增殖药物的用途
CN113171319B (zh) 2021-05-07 2022-03-08 宝萃生物科技有限公司 一种即时、长效抗衰除皱的复合植物提取物及其制备方法和应用
CN113476362B (zh) 2021-06-23 2022-09-13 植物医生(广东)生物科技有限公司 一种面部皮肤角质更新促进剂及其应用
WO2023031673A1 (en) 2021-08-30 2023-03-09 Amazentis Sa Treating long covid-19 with urolithins
CN113855758A (zh) 2021-11-02 2021-12-31 顾佳圻 一种益寿补钙丸及其制备方法
EP4482947A1 (en) 2022-02-24 2025-01-01 Amazentis SA Uses of urolithins
CA3246412A1 (en) 2022-03-22 2023-09-28 Amazentis Sa COMPOSITIONS
CN114794490B (zh) 2022-05-25 2023-07-25 江南大学 一种具有抗皮肤光老化及辅助减脂功能的组合物
WO2023237926A2 (en) 2022-06-06 2023-12-14 Amazentis Sa Urolithins for improving cardiac function and health
WO2024246603A1 (en) 2023-05-26 2024-12-05 Amazentis Sa Urolithin for improving performance in elite and sub-elite athletes
WO2024246601A1 (en) 2023-05-26 2024-12-05 Amazentis Sa Compositions comprising trigonelline and urolithin
GB202312220D0 (en) 2023-08-09 2023-09-20 Amazentis Sa Formulation
CN116889583B (zh) 2023-08-26 2024-07-23 琛蓝(美国)营养制品股份有限公司 一种富含稀有人参皂苷的人参提取物的制备方法及其应用
FR3153998A1 (fr) 2023-10-13 2025-04-18 L'oreal Utilisation cosmétique d’iso-urolithine A sur une peau sensible
WO2025078645A1 (en) 2023-10-13 2025-04-17 L'oreal Cosmetic use of at least urolithin b or c on a sensitive skin
GB202316295D0 (en) 2023-10-24 2023-12-06 Amazentis Sa Composition
GB202319994D0 (en) 2023-12-22 2024-02-07 Amazentis Sa Compositions for use

Similar Documents

Publication Publication Date Title
JP2015523362A5 (https=)
Torres et al. Features, diagnosis, and treatment of nonalcoholic fatty liver disease
IN2014CN04055A (https=)
JP2012097105A5 (https=)
MY173699A (en) Novel compounds for the treatment of diseases associated with amyloid of amyloid-like proteins
CN113924089A (zh) 使用一种或多种自噬诱发氨基酸来增强一种或多种合成代谢氨基酸的肌肉骨骼效应的组合物和方法
MX2010008371A (es) Inhibidores de catepsina b.
EP4294210B1 (en) Methods and compositions using combinations of lactobacillus mucosae and soluble dietary fiber
JP2014510741A5 (https=)
EA201001781A1 (ru) Применение гликозаминогликанов для перорального введения и композиции гликозаминогликанов
EP2598158A4 (en) Pharmaceutical compositions for the treatment of left ventricular diastolic dysfunction comprising an apolipoprotein peptide/phospholipid complex
JP2011046708A5 (https=)
CN112851660A (zh) 含有小檗碱的酸-碱加成盐、其制备方法及其作为药物的用途
WO2008112840A3 (en) Novel composition and methods for the treatment of immune related diseases
JP2009502777A5 (https=)
EP2231148A4 (en) Pharmaceutical composition for the treatment and prevention of heart disease
JP2014520854A5 (https=)
JP7068704B2 (ja) 老化抑制剤、軟部組織の石灰化抑制剤、及び肺組織破壊抑制剤
EA201990883A1 (ru) Соли берберина, соли урсодезоксихолевой кислоты и их комбинации, способы получения и применения
JP6910187B2 (ja) Ｔｒｐｖ４活性抑制剤
WO2020075764A1 (ja) Ｔｒｐｖ４活性抑制剤
JP2022135978A (ja) チロシンフェノールリアーゼによるフェノール生成及び／又はトリプトファンインドールリアーゼによるインドール生成の阻害剤
JP2023501058A (ja) ベータ－ラパコンを有効成分として含む胆汁うっ滞性肝疾患予防又は治療用薬学組成物
Min et al. Verruciform xanthoma arising in the mid esophagus.
CN1908001A (zh) 胆汁酸衍生物及其医药用途